Literature DB >> 22410287

Insulin stimulates IGFBP-2 expression in 3T3-L1 adipocytes through the PI3K/mTOR pathway.

Zhuo Li1, Stéphanie Miard, Mathieu Laplante, Nahum Sonenberg, Frédéric Picard.   

Abstract

Insulin-like growth factor binding protein 2 (IGFBP-2) has been implicated in the etiology of several diseases, including the metabolic syndrome. Although IGFBP-2 derives mostly from the liver, recent evidence in mice and humans indicate that aging and obesity are associated with altered IGFBP-2 levels in white adipocytes. The present study was aimed at determining the mechanisms that control IGFBP-2 expression in mature adipocytes. IGFBP-2 mRNA and protein expression in serum-deprived 3T3-L1 adipocytes were twofold increased by acute insulin treatment. Co-treatments with the phosphatidylinositol 3-kinase (PI3K) inhibitor wortmannin or the mammalian target of rapamycin (mTOR) inhibitor rapamycin blunted the effects of insulin. Coherently, IGFBP-2 mRNA levels were robustly increased in adipocytes lacking either TSC2 or 4E-BP1. Insulin triggered the recruitment of CAAT/enhancer binding protein α (C/EBPα) to the IGFBP-2 proximal promoter. These findings suggest that insulin upregulates IGFBP-2 expression through a PI3K/mTOR/C/EBPα pathway in white adipocytes.
Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22410287     DOI: 10.1016/j.mce.2012.02.022

Source DB:  PubMed          Journal:  Mol Cell Endocrinol        ISSN: 0303-7207            Impact factor:   4.102


  8 in total

1.  IGFBP-2 and aging: a 20-year longitudinal study on IGFBP-2, IGF-I, BMI, insulin sensitivity and mortality in an aging population.

Authors:  Annewieke W van den Beld; Olga D Carlson; Maire E Doyle; Dimitris Rizopoulos; Luigi Ferrucci; Aart Jan van der Lely; Josephine M Egan
Journal:  Eur J Endocrinol       Date:  2019-02-01       Impact factor: 6.664

2.  Glucagon Decreases IGF-1 Bioactivity in Humans, Independently of Insulin, by Modulating Its Binding Proteins.

Authors:  Zeinab Sarem; Christiane Bumke-Vogt; Ayman M Mahmoud; Biruhalem Assefa; Martin O Weickert; Aikatarini Adamidou; Volker Bähr; Jan Frystyk; Matthias Möhlig; Joachim Spranger; Stefanie Lieske; Andreas L Birkenfeld; Andreas F H Pfeiffer; Ayman M Arafat
Journal:  J Clin Endocrinol Metab       Date:  2017-09-01       Impact factor: 5.958

Review 3.  Diminished mTOR signaling: a common mode of action for endocrine longevity factors.

Authors:  Dudley W Lamming
Journal:  Springerplus       Date:  2014-12-15

4.  Mice endometrium receptivity in early pregnancy is impaired by maternal hyperinsulinemia.

Authors:  Runqin Li; Juan Wu; Junlin He; Yingxiong Wang; Xueqing Liu; Xuemei Chen; Chao Tong; Yubin Ding; Yan Su; Wenqi Chen; Chen Zhang; Rufei Gao
Journal:  Mol Med Rep       Date:  2017-03-14       Impact factor: 2.952

Review 5.  Recent Insights into Insulin-Like Growth Factor Binding Protein 2 Transcriptional Regulation.

Authors:  Minsang Shin; Hye Suk Kang; Jae Hyung Park; Jae Hoon Bae; Dae Kyu Song; Seung Soon Im
Journal:  Endocrinol Metab (Seoul)       Date:  2017-01-19

Review 6.  Potential Role of Insulin Growth-Factor-Binding Protein 2 as Therapeutic Target for Obesity-Related Insulin Resistance.

Authors:  Hatim Boughanem; Elena M Yubero-Serrano; José López-Miranda; Francisco J Tinahones; Manuel Macias-Gonzalez
Journal:  Int J Mol Sci       Date:  2021-01-24       Impact factor: 5.923

7.  IGFBP-2 partly mediates the early metabolic improvements caused by bariatric surgery.

Authors:  Justine Faramia; Zheng Hao; Michael B Mumphrey; R Leigh Townsend; Stéphanie Miard; Anne-Marie Carreau; Mélanie Nadeau; Frédérique Frisch; Elena-Dana Baraboi; Thomas Grenier-Larouche; Christophe Noll; Meng Li; Laurent Biertho; Simon Marceau; Frédéric-Simon Hould; Stéfane Lebel; Christopher D Morrison; Heike Münzberg; Denis Richard; André C Carpentier; André Tchernof; Hans-Rudolf Berthoud; Frédéric Picard
Journal:  Cell Rep Med       Date:  2021-04-20

Review 8.  The Insulin-Like Growth Factor System in Obesity, Insulin Resistance and Type 2 Diabetes Mellitus.

Authors:  Moira S Lewitt; Mairi S Dent; Kerstin Hall
Journal:  J Clin Med       Date:  2014-12-22       Impact factor: 4.241

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.